B · Normal
[Eli Lilly announced new data on the combination treatment of Taltz and Zepbound. Disease activity and metabolic indicators improved in patients with psoriatic arthritis] On November 11, Eli Lilly (LLY) announced the Phase IIIb clinical data of the combination of Taltz (ixekizumab, ixekizumab) and Zepbound (tirzepatide, tilpotide) in the treatment of patients with psoriatic arthritis and obesity. The study showed that compared with Taltz alone, combined use of Zepbound achieved positive results in terms of disease activity, patient-reported outcomes and metabolic markers after one year of treatment. Relevant data come from the TOGETHER-PsA study.
Comments